- Home
- CGAU vs EWTX Comparison
CGAU vs EWTX Comparison
Compare CGAU & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGAU
- EWTX
- Stock Information
- Founded
- CGAU 2002
- EWTX 2017
- Country
- CGAU Canada
- EWTX United States
- Employees
- CGAU N/A
- EWTX N/A
- Industry
- CGAU Precious Metals
- EWTX Biotechnology: Pharmaceutical Preparations
- Sector
- CGAU Basic Materials
- EWTX Health Care
- Exchange
- CGAU Nasdaq
- EWTX Nasdaq
- Market Cap
- CGAU 1.6B
- EWTX 1.5B
- IPO Year
- CGAU N/A
- EWTX 2021
- Fundamental
- Price
- CGAU $11.38
- EWTX $15.65
- Analyst Decision
- CGAU Buy
- EWTX Buy
- Analyst Count
- CGAU 3
- EWTX 10
- Target Price
- CGAU $12.83
- EWTX $37.90
- AVG Volume (30 Days)
- CGAU 2.4M
- EWTX 980.1K
- Earning Date
- CGAU 10-28-2025
- EWTX 11-06-2025
- Dividend Yield
- CGAU 1.76%
- EWTX N/A
- EPS Growth
- CGAU N/A
- EWTX N/A
- EPS
- CGAU 0.33
- EWTX N/A
- Revenue
- CGAU $1,214,156,000.00
- EWTX N/A
- Revenue This Year
- CGAU $5.72
- EWTX N/A
- Revenue Next Year
- CGAU $9.19
- EWTX N/A
- P/E Ratio
- CGAU $30.67
- EWTX N/A
- Revenue Growth
- CGAU N/A
- EWTX N/A
- 52 Week Low
- CGAU $5.41
- EWTX $10.60
- 52 Week High
- CGAU $11.58
- EWTX $38.12
- Technical
- Relative Strength Index (RSI)
- CGAU 89.35
- EWTX 53.97
- Support Level
- CGAU $10.21
- EWTX $14.85
- Resistance Level
- CGAU $11.58
- EWTX $16.43
- Average True Range (ATR)
- CGAU 0.34
- EWTX 1.06
- MACD
- CGAU 0.14
- EWTX 0.02
- Stochastic Oscillator
- CGAU 92.21
- EWTX 57.14
About CGAU Centerra Gold Inc.
Centerra Gold Inc a gold mining and exploration company engaged in the operation, exploration, development, and acquisition of gold properties in Asia, North America, and other markets world-wide. The company reportable operating segments are Oksut; Mount; and Milligan Molybdenum. It derives maximum revenue from Oksut segment. Geographically, it operates in Turkey, United States, Canada and Other.
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.